Glenmark Pharmaceuticals Inc., USA: Drug Recall

Recall #D-0246-2026 · 12/30/2025

Class II: Risk

Recall Details

Recall Number: D-0246-2026
Classification: Class II
Product Type: Drug
Recalling Firm: Glenmark Pharmaceuticals Inc., USA
Status: Ongoing
Date Initiated: 12/30/2025
Location: Elmwood Park, NJ, United States
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 96,948 packs

Reason for Recall

Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.

Product Description

Ondansetron Orally Disintegrating Tablets, USP, 4mg, 30 Tablets (3 blistercards each containing 10 tablets), Rx only, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430, Product of India, NDC 68462-157-13

Distribution Pattern

Nationwide within the United States

Other Recalls by Glenmark Pharmaceuticals Inc., USA

Class III: Low Risk 11/21/2025

Cross Contamination with Other Products: Testing of reserve samples showed presence of traces of ezetimibe
Class III: Low Risk 11/18/2025

Cross Contamination with Other Products
Class II: Risk 09/17/2025

CGMP Deviations: Market complaints received for gritty texture (grainy)
Class II: Risk 09/03/2025

Failed Impurities/Degradation Specifications
Class II: Risk 08/08/2025

Failed Dissolution Specifications: Failure results (above) were reported for the Dissolution (by UV) test for commercial annual stability at the long-term shelf life stability interval, wherein the dissolution results do not comply with L3 stage dissolution criteria.

View all recalls by Glenmark Pharmaceuticals Inc., USA →

Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.